Chinese pharmaceutical services giant WuXi AppTec has come under renewed pressure after the US Department of Defense added the company to its list of firms allegedly associated with China’s military.
The move has sparked concerns across the pharmaceutical industry, as WuXi AppTec plays a critical role in drug research, development, and manufacturing for several of the world’s largest pharmaceutical companies, including major US drugmakers.
Following the announcement, WuXi AppTec’s shares fell sharply, dropping as much as 6 per cent in Hong Kong trading and more than 5 per cent on mainland Chinese exchanges.
Why the Pentagon’s Decision Matters
The Pentagon’s designation is tied to the implementation of the Biosecure Act, legislation designed to reduce American dependence on Chinese biotechnology and pharmaceutical companies.
Under the law, US government agencies are prohibited from entering into contracts with organizations that rely on services provided by companies identified as “Chinese military companies” by the Defense Department.
The development could have significant consequences for WuXi AppTec’s business, particularly because the United States remains its largest market.
According to industry estimates, nearly three-quarters of the company’s revenue in 2025 came from US-based clients, making the designation a potentially major financial setback.
Impact on US Drugmakers
WuXi AppTec has long served as a key partner for pharmaceutical companies involved in drug discovery, clinical research, and manufacturing.
One of its most notable roles has been in the production chain for obesity treatments. Bloomberg previously reported that WuXi AppTec manufactured a substantial portion of the active pharmaceutical ingredient used in Zepbound, the blockbuster weight-loss drug developed by Eli Lilly and Company.
Because many US pharmaceutical firms depend on WuXi AppTec’s research and manufacturing capabilities, any restrictions resulting from the Pentagon’s decision could force companies to seek alternative suppliers and contract research partners.
Industry analysts warn that such transitions could increase costs, delay projects, and complicate ongoing drug development programmes.
Billions of Dollars in Revenue at Risk
Analysts believe the designation could have long-term financial implications for WuXi AppTec.
According to estimates cited by market observers, approximately 206 billion yuan (around $30.4 billion) in US-related revenue could be exposed between 2027 and 2030 if customers gradually move away from the company’s services.
The Biosecure Act allows existing contracts to continue for a transition period, giving US clients up to five years to phase out relationships with affected companies.
This grace period is intended to prevent sudden disruptions to pharmaceutical research and manufacturing operations.
WuXi AppTec Rejects the Allegations
WuXi AppTec has strongly denied any connection to the Chinese military.
In a statement, the company described the Pentagon’s designation as “clearly a mistake” and argued that it does not meet the legal criteria required for inclusion on the list.
The company further stated that it is neither controlled by nor affiliated with any Chinese military or government entity.
WuXi AppTec also announced plans to challenge the designation and pursue corrective measures through appropriate legal and administrative channels.
Growing US-China Tensions in Healthcare
The latest move reflects broader efforts by Washington to reduce strategic dependence on China in critical sectors, including biotechnology, pharmaceuticals, semiconductors, and advanced manufacturing.
In recent years, policymakers have increasingly voiced concerns about supply-chain security, particularly after disruptions experienced during the COVID-19 pandemic highlighted the risks of concentrated manufacturing networks.
The designation of WuXi AppTec adds another layer of complexity to an already strained US-China relationship and may accelerate efforts by pharmaceutical companies to diversify their research and manufacturing operations.
WuXi Biologics Not Included
While WuXi AppTec has been added to the Pentagon’s list, its sister company, WuXi Biologics, has not been included in the designation.
The distinction may provide some relief to biotechnology companies that rely on WuXi Biologics for biologics development and manufacturing services.
However, analysts say the broader uncertainty surrounding Chinese pharmaceutical service providers is likely to remain a key concern for global healthcare companies.